OVERVIEW OF THE BRAZILIAN OUTCOMES FROM FIRST MULTICENTRIC STUDY WITH USE FROM DATABASE CIBMTR. A PILOT STUDY.

Autores

  • Cinthya Corrêa da Silva Hospital Israelita Albert Einstein
  • Leonardo Javier Arcuri Hospital Israelita Albert Einstein
  • Anderson João Simione Hospital Amaral Carvalho
  • Heliz Regina Alves das Neves Hospital de Clínicas – Universidade Federal do Paraná
  • Bruna Letícia da Silva Santos Geraldo Bio Sana's Serviços Médicos
  • Afonso Celso Vigorito Universidade Estadual de Campinas
  • Vaneuza Araújo Moreira Funke Hospital de Clínicas – Universidade Federal do Paraná
  • Marcos Paulo Colella Universidade Estadual de Campinas
  • Andreza Alice Feitosa Ribeiro Hospital Israelita Albert Einstein
  • Vanderson Geraldo Rocha Hospital das Clinicas da Universidade de São Paulo
  • Iracema Esteves Hospital Israelita Albert Einstein
  • Carmem Bonfim Hospital de Clínicas – Universidade Federal do Paraná
  • Victor Gottardello Zecchin Grupo de Apoio ao Adolescente e à Criança com Câncer
  • Fernando Barroso Duarte Hospital Universitário Walter Cantídio
  • Roberto Luiz da Silva Bio Sana's Serviços Médicos
  • Cintia Monteiro Grupo de Apoio ao Adolescente e à Criança com Câncer
  • Germison Silva Lopes Hospital Universitário Walter Cantídio
  • Larissa Codogno Guzelotto Universidade Estadual de Campinas
  • Samir Nabhan Hospital de Clínicas – Universidade Federal do Paraná
  • Vergílio Antonio Rensi Colturato Hospital Amaral Carvalho
  • Nelson Hamerschlak Hospital Israelita Albert Einstein

DOI:

https://doi.org/10.46765/2675-374X.2020v2n1p55-62

Palavras-chave:

Hematopoietic Cell Transplant, CIBMTR, Outcomes, Cox model, Kaplan Meier, Outcomes and Brazil.

Resumo

To better understand the outcomes of HSCT in Brazil, we conducted a multicenter study using the CIBMTR database. Seven participating centers extracted their own data through the Data Back to Center tool. Main indications for HSCT-auto were MM(51%), NHL(18%) and HL(17%); Allogeneic, AML(24%), ALL(23%) and SAA(15%). For acute leukemias, risk of death was higher in the 18-40 years group (HR=1.18,p=0.022), 40-60(HR=1.19,p<0.001) and 60+(HR=1.39,p=0.007), compared with 0-18 years, in ALL (HR=1.05,p <0.001, compared with AML) and with partially-matched related donor (HR=1.59,p= 0.003, compared with matched sibling), while URD was not. HSCT in CR2+(HR=1.28,p=0.01) and relapse (HR=2.44,p< 0.001) were risk factors for death. 49%(95CI:44-52)52%(95CI:43-62)45%(95CI:39-51) and 55%(95CI:49-63), somewhat poorer than the CIBMTR: 62 and 70%, respectively.  Limited access to novel drugs for most centers and lack of molecular risk information are possible explanations for these differences. Further studies are necessary to better evaluate our findings and the DBtC tool enables multicenter studies.

Downloads

Publicado

14/10/2020 — Atualizado em 01/10/2021

Versões

Como Citar

da Silva, C. C., Arcuri, L. J., Simione, A. J., das Neves, H. R. A., Geraldo, B. L. da S. S., Vigorito, A. C., Funke, V. A. M., Colella, M. P., Ribeiro, A. A. F., Rocha, V. G., Esteves, I., Bonfim, C., Zecchin, V. G., Duarte, F. B., da Silva, R. L., Monteiro, C., Lopes, G. S., Guzelotto, L. C., Nabhan, S., Colturato, V. A. R., & Hamerschlak, N. (2021). OVERVIEW OF THE BRAZILIAN OUTCOMES FROM FIRST MULTICENTRIC STUDY WITH USE FROM DATABASE CIBMTR. A PILOT STUDY. JBMTCT, 1(3), 55–62. https://doi.org/10.46765/2675-374X.2020v2n1p55-62 (Original work published 14º de outubro de 2020)

Edição

v. 1 n. 3 (2020): Journal of Bone Marrow Transplantation and Cellular Therapy

Seção

Artigos

Licença

Copyright (c) 2020 JBMTCT

Creative Commons License

Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

License and Copyright Policy

The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.

  1. License

    • All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
    • This license permits anyone to:
      • Share: Copy and redistribute the material in any medium or format.
      • Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
    • The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.

    More information about the license can be found here: Creative Commons Attribution 4.0 International License.

  2. Authors’ Rights

    • Authors retain the copyright to their work.
    • Authors grant JBMTCT the right to publish the work and make it openly accessible online.
    • Authors are free to:
      • Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
      • Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.

  3. No Embargo

    • There is no embargo period; articles are made freely available immediately upon publication.

  4. Ethical Use

    • Users of JBMTCT articles must ensure proper citation of the authors and the journal.
    • Articles must not be used in ways that violate ethical or legal standards.

  5. Disclaimer

    • While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.

For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br 

JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.

 

Artigos mais lidos pelo mesmo(s) autor(es)

1 2 3 4 5 6 > >>